Tools for modelling blood-brain barrier penetrability

Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates

Volumn , Issue , 2011, Pages 166-188

  Veszelka, Szilvia ^a   Kittel, Ágnes ^a   Deli, Mária A ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882591848     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805120511101010166     Document Type: Chapter

References (175)

1. Pardridge WM. Drug and gene targeting to brain with molecular Trojan horses. Nat Rev Drug Discov 2002, 1(2): 131-139.
2. Deli MA. Drug Transport and the Blood-Brain Barrier (Chapter 10). In: Tihanyi K, Vastag M, editors. Solubility, Delivery, and ADME Problems of Drugs and Drug Candidates, Bentham Science Publishers Ltd, 2010; pp. 1-27.
3. Vastag M, Keseru GM. Current in vitro and in silico models of blood-brain barrier penetration: a practical view. Curr Opin Drug Discov Devel 2009, 12(1): 115-124.
4. Deli MA, Ábrahám CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology and pharmacology. Cell Mol Neurobiol 2005, 25(1): 59-127.
5. Abbott NJ. Prediction of blood-brain barrier permeation in drug discovery from in vivo, in vitro and in silico models. Drug Discov Today Technol 2004, 1(4): 407-416.
6. Goodwin JT, Clark DE. In silico predictions of blood-brain barrier penetration: considerations to "keep in mind". J Pharmacol Exp Ther 2005, 315(2): 477-483.
7. Garg A, Verma J, Roy N. In silico modeling for blood-brain barrier permeability predictions. In: Erhardt C, Kim K-J, Editors. Drug Absorption Studies. In Situ, In vivo and In Silico Models, Vol. VII, Biotechnology: Pharmaceutical Aspects, New York, NY, Springer, 2008; pp. 510-556.
8. Mensch J, Oyarzabal J, Mackie C, Augustijns P. In vivo, in vitro and in silico methods for small molecule transfer across the BBB. J Pharm Sci 2009, 98(12): 4429-4468.
9. Konovalov DA, Coomans D, Deconinck E, Heyden YV. Benchmarking of QSAR models for blood-brain permeation. J Chem Inf Model 2007, 47(4): 1648-1656.
10. Liu X, Tu M, Kelly RS, Chen C, Smith BJ. Development of a computational approach to predict blood-brain barrier permeability. Drug Metab Dispos 2004, 32(1): 132-139.
11. Abraham MH. The factors that influence permeation across the blood-brain barrier. Eur J Med Chem 2004, 39(3): 235-240.
12. Bendels S, Kansy M, Wagner B, Huwyler J. In silico prediction of brain and CSF permeation of small molecules using PLS regression models. Eur J Med Chem 2008, 43(8): 1581-1592.
13. Glave WR, Hansch C 1972 Relationship between lipophilic character and anesthetic activity. J Pharm Sci 1972; 61(4): 589-591.
14. Rapoport SI, Levitan H. Neurotoxicity of X-ray contrast media. Relation to lipid solubility and blood-brain barrier permeability. Am J Roentgenol 1974, 122(1): 186-193.
15. Levin VA. Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J Med Chem 1980, 23(6): 682-684.
16. Young RC, Mitchell RC, Brown TH, et al. Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists. J Med Chem 1988, 31(3): 656-671.
17. Pajouhesh H, Lenz GR. Medicinal chemical properties of successful central nervous system drugs. NeuroRx 2005, 2(4): 541-553.
18. Van de Waterbeemd H, Camenisch G, Folkers G, Chretien JR, Raevsky OA. Estimation of blood-brain barrier crossing of drugs using molecular size and shape, and H-bonding characteristics. J Drug Target 1998, 6(2): 151-165.
19. Van de Waterbeemd H, Kansy M. Hydrogen-bonding capacity and brain penetration. Chimia 1992, 46(7-8): 299-303.
20. Adenot M, Lahana R. Blood-brain barrier permeation models: discriminating between potential CNS and non-CNS drugs including P-glycoprotein substrates. J Chem Inf Comput Sci 2004, 44(1): 239-248.
21. Chen Y, Zhu Q-J, Pan J, Yang Y, Wu X-P. A prediction model for blood-brain barrier permeation and analysis on its parameter biologically. Comput Meth Prog Biomed 2009, 95(3): 280-287.
22. Van Damme S, Langenaeker W, Bultinck P. Prediction of blood-brain partitioning: a model based on ab initio calculated quantum chemical descriptors. J Mol Graph Model 2008, 26(8): 1223-1236.
23. Hansch C, Björkroth JP, Leo A. Hydrophobicity and central nervous system agents: on the principal of minimal hydrophobicity in drug design. J Pharm Sci 1987, 76(6): 663-687.
24. Lipinski CA. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov Today Technol 2004, 1(4): 337-341.
25. Hitchcock SA, Pennington LD. Structure-brain exposure relationships. J Med Chem 2006, 49(26): 7559-7583.
26. Hitchcock SA. Blood-brain barrier permeability considerations for CNS-targeted compound library design. Curr Opin Chem Biol 2008, 12(3): 318-323.
27. Pan D, Iyer M, Liu J, Li Y, Hopfinger AJ. Constructing optimum blood brain barrier QSAR models using a combination of 4D-molecular similarity measures and cluster analysis. J Chem Inf Comput Sci 2004, 44(6): 2083-2098.
28. Gerebtzoff G, Seelig A. In silico prediction of blood-brain barrier permeation using the calculated molecular crosssectional area as main parameter. J Chem Inf Mod 2006, 46(6): 2638-2650.
29. Li H, Yap CW, Ung CY, Xue Y, Cao ZW, Chen YZ. Effect of selection of molecular descriptors on the prediction of blood-brain barrier penetrating and nonpenetrating agents by statistical learning methods. J Chem Inf Model 2005, 45(5): 1376-84.
30. Narayanan R, Gunturi SB. In-silico ADME modelling: prediction models for blood-brain barrier permeation using systemic variable selection methods. Bioorg Med Chem 2005, 13(8): 3017-3028.
31. Katritzky AR, Kuanar M, Slavov S, et al. Correlation of blood-brain penetration using structural descriptors. Bioorg Med Chem 2006, 14(14): 4888-4917.
32. Engkvist O, Wrede P, Rester U. Prediction of CNS activity of compound libraries using substructure analysis. J Chem Inf Comput Sci 2003, 43(1): 155-160.
33. Yap CW, Chen YZ. Quantitative Structure-Pharmacokinetic Relationships for drug distribution properties by using general regression neural network. J Pharm Sci 2005, 94(1): 153-68.
34. Klon AE, Lowrie JF, Diller DJ. Improved naïve Bayesian modelling of numerical data for absorption, distribution, metabolism and excretion (ADME) property prediction. J Chem Inf Model 2006, 46(5): 1945-1956.
35. Ajay A, Bemis GW, Murcko MA. Designing libraries with CNS activity. J Med Chem 1999, 42(24): 4942-4951.
36. Kortagere S, Chekmarev D, Welsh WJ, Ekins S. New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res 2008, 25(8): 1836-1845.
37. Zhang L, Zhu H, Oprea TI, Golbraikh A, Tropsha A. QSAR modeling of the blood-brain barrier permeability for diverse organic compounds. Pharm Res 2008, 25(8): 1902-1914.
38. Obrezanova O, Csányi G, Gola JM, Segall MD. Gaussian procedure: a method for automatic QSAR modeling of ADME properties. J Chem Inf Model 2007, 47(5): 1847-1857.
39. Deconinck E, Zhang MH, Coomans D, van der Heyden Y. Classification tree models for the prediction of blood-brain barrier passage of drugs. J Chem Inf Model 2006, 46(3): 1410-1419.
40. Zhao YH, Abraham MH, Ibrahim A, et al. Predicting penetration across the blood-brain barrier from simple descriptors and fragmentation schemes. J Chem Inf Model 2007, 47(1): 170-175.
41. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46(1-3): 3-26.
42. Abraham MH, Takács-Novák K, Mitchell RC. On the partition of ampholytes: application to blood-brain distribution. J Pharm Sci 1997, 86(3): 310-315.
43. Liu X, Chen C, Smith BJ. Progress in brain penetration evaluation in drug discovery and development. J Pharmacol Exp Ther 2008, 325(2): 349-356.
44. Kansy M, Senner F, Gubernator K. Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. J Med Chem 1998, 41(7): 1007-1010.
45. Salminen T, Pulli A, Taskinen J. Relationship between immobilised artificial membrane chromatographic retention and the brain penetration of structurally diverse drugs. J Pharm Biomed Anal 1997, 15(4): 469-477.
46. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT. High throughput artificial membrane permeability assay for bloodbrain barrier. Eur J Med Chem 2003, 38(3): 223-232.
47. Di L, Kerns EH, Hong Y, Kleintop TA, McConnell OJ, Huryn DM. Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. J Biomol Screen 2003, 8(4): 453-462.
48. Carrara S, Reali V, Misiano P, Dondio G, Bigogno C. Evaluation of in vitro penetration: optimized PAMPA and MDCKII-MDRI assay comparison. Int J Pharm 2007, 345(1-2): 125-133.
49. Mensch J, Melis A, Mackie C, Verreck G, Brewster ME, Augustijns P. Evaluation of various PAMPA models to identify the most discriminating method for the prediction of BBB permeability. Eur J Pharm Biopharm 2010, 74(3): 495-502.
50. Nielsen PE, Avdeef A. PAMPA-a drug absorption in vitro model 8. Apparent filter porosity and the unstirred water layer. Eur J Pharm Sci 2004, 22(1): 33-41.
51. McAllister MS, Krizanac-Bengez L, Macchia F, et al. Mechanisms of glucose transport at the blood-brain barrier: an in vitro study. Brain Res 2001, 904(1): 20-30.
52. Stanness KA, Westrum LE, Fornaciari E, et al. Morphological and functional characterization of an in vitro blood-brain barrier model. Brain Res 1997, 771(2): 329-342.
53. Sinclair CJ, Krizanac-Bengez L, Stanness KA, Janigro D, Parkinson FE. Adenosine permeation of a dynamic in vitro blood-brain barrier inhibited by dipyridamole. Brain Res 2001, 898(1): 122-125.
54. Santaguida S, Janigro D, Hossain M, Oby E, Rapp E, Cucullo L. Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Brain Res 2006, 1109(1): 1-13.
55. Garberg P, Ball M, Borg N, et al. In vitro models of the blood-brain barrier. Toxicol in Vitro 2005, 19(3): 299-334.
56. Wang Q, Ragre JD, Weinstein K, et al. Evaluation of the MDR-MDCK cell line as a permeability screen for the bloodbrain barrier. Int J Pharm 2005, 288(2): 349-359.
57. Batrakova EV, Li S, Miller DW, Kabanov AV. Pluronic P85 increases permeability of a broad spectrum of drugs in polarized BBMEC and Caco-2 cell monolayers. Pharm Res 1999, 16(9): 1366-1372.
58. Lundquist S, Renftel M, Brillault J, Fénart L, Cecchelli R, Dehouck M-P. Prediction of drug transport through the bloodbrain barrier in vivo: a comparison between two in vitro cell models. Pharm Res 2002, 19(7): 976-981.
59. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007, 6(8): 650-661.
60. Hellinger É, Bakk ML, Pócza P, Tihanyi K, Vastag M. Drug penetration model of vinblastine-treated Caco-2 cultures. Eur J Pharm Sci 2010, 41(1): 96-106.
61. Barar J, Gumbleton M, Asadi M, Omidi Y. Barrier functionality and transport machineries of human ECV304 cells. Med Sci Monit 2010; 16(1): BR52-BR60.
62. Neuhaus W, Plattner VE, Wirth M, et al. Validation of in vitro cell culture models of the blood-brain barrier: tightness characterization of two promising cell lines. J Pharm Sci 2008, 97(12): 5158-5175.
63. Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice-Evans C. Interaction between flavonoids and the blood-brain barrier: in vitro studies. J Neurochem 2003, 85(1): 180-192.
64. Cucullo L, Hossain M, Rapp E, Manders T, Marchi N, Janigro D. Development of a humanized in vitro blood-brain barrier model to screen for brain penetration of antiepileptic drugs. Epilepsia 2007, 48(3): 505-516.
65. Cucullo L, Couraud PO, Weksler B, et al. Immortalized human brain endothelial cells and flow-based vascular modeling: a marriage of convenience for rational neurovascular studies. J Cereb Blood Flow Metab 2008, 28(2): 312-328.
66. Fogh J, Fogh JM, Orfeo T. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977, 59(1): 221-226.
67. Fogh J, Orfeo T, Tiso J, Sharkey FE. Establishment of human colon carcinoma lines in nude mice. Exp Cell Biol. 1979, 47(2): 136-144.
68. Braun A, Hämmerle S, Suda K, et al. Cell cultures as tools in biopharmacy. Eur J Pharm Sci 2000; 11 (Suppl 2): S51-S60.
69. Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 2001, 46(1-3): 27-43.
70. Hayeshi R, Hilgendorf C, Artursson P, et al. Comparison of drug transporter gene expression and functionality in Caco-2 cells from 10 different laboratories. Eur J Pharm Sci 2008, 35(5): 383-396.
71. rown J, Reading SJ, Jones S, et al. Critical evaluation of ECV304 as a human endothelial cell model defined by genetic analysis and functional responses: a comparison with the human bladder cancer derived epithelial cell line T24/83. Lab Invest 2000, 80(1): 37-45.
72. Kiessling F, Kartenbeck J, Haller C. Cell-cell contacts in the human cell line ECV304 exhibit both endothelial and epithelial characteristics. Cell Tissue Res 1999, 297(1): 131-140.
73. Suda K, Rothen-Rutishauser B, Günthert M, Wunderli-Allenspach H. Phenotypic characterization of human umbilical vein endothelial (ECV304) and urinary carcinoma (T24) cells: endothelial versus epithelial features. In vitro Cell Dev Biol Anim 2001, 37(8): 505-514.
74. Gumbleton M, Audus KL. Progress and limitations in the use of in vitro cell cultures to serve as a permeability screen for the blood-brain barrier. J Pharm Sci 2001, 90(1): 1681-1698.
75. Reichel A, Begley DJ, Abbott NJ. An overview of in vitro techniques for blood-brain barrier studies. In: Nag S, Ed. The Blood-Brain Barrier: Biology and Research Protocols, Vol. 89, Methods Molecular Medicine, Totowa, NJ, Humana Press, 2003; pp. 307-324.
76. Joó F, Karnushina I. A procedure for the isolation of capillaries from rat brain. Cytobios 1973, 8(29): 41-48.
77. Joó F. The blood-brain barrier in vitro: ten years of research on microvessels isolated from the brain. Neurochem Int 1985, 7(1): 1-25.
78. Joó F. The blood-brain barrier in vitro: the second decade. Neurochem Int 1993, 23(6): 499-521.
79. Enerson BE, Drewes LR. The rat blood-brain barrier transcriptome. J Cereb Blood Flow Metab 2006, 26(7): 959-973.
80. Bickel U. How to measure drug transport across the blood-brain barrier. NeuroRx 2005, 2(1): 15-26.
81. Panula P, Joó F, Rechardt L. Evidence for the presence of viable endothelial cells in cultures derived from dissociated rat brain. Experientia 1978, 34(1): 95-97.
82. Deli MA. Blood-Brain Barrier Models. In: Lajtha A, Ed. Handbook of Neurochemistry and Molecular Neurobiology, Neural Membranes and Transport, Vol. 11, New York, Springer, 2007; pp. 29-56.
83. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nature Rev Neurosci 2006, 7(1): 41-53.
84. Sun H, Miller DW, Elmquist WF. Effect of probenecid on fluorescein transport in the central nervous system using in vitro and in vivo models. Pharm Res 2001, 18(11): 1542-1549.
85. Gaillard PJ, de Boer AG. Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of a drug. Eur J Pharm Sci 2000, 12(2): 95-102.
86. Haseloff RF, Blasig IE, Bauer H-C, Bauer H. In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol Neurobiol 2005, 25(1): 25-39.
87. Nakagawa S, Deli MA, Nakao S, et al. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol 2007, 27(6): 687-694.
88. Nakagawa S, Deli MA, Kawaguchi H, et al. A new blood-brain barrier model using brain endothelial cells, pericytes and astrocytes. Neurochem Int 2009, 54(3-4): 253-263.
89. Abbott NJ, Hughes CCW, Revest PA, Greenwood J. Development and characterisation of a rat brain capillary endothelial culture: towards an in vitro blood-brain barrier. J Cell Sci 1992, 103(Pt 1): 23-37.
90. Deli MA, Joó F, Krizbai I, Lengyel I, Nunzi MG, Wolff J. Calmodulin/calmodulin-stimulated protein kinase II is present in primary cultures of cerebral endothelial cells. J Neurochem 1993, 60(5): 1960-1963.
91. Szabó CA, Deli MA, Ngo DTK, Joó F. Production of pure primary rat cerebral endothelial cell culture: a comparison of different methods. Neurobiology (Bp) 1997, 5(1): 1-16.
92. Parkinson FE, Hacking C. Pericyte abundance affects sucrose permeability in cultures of rat brain microvascular endothelial cells. Brain Res 2005, 1049(1): 8-14.
93. Perrière N, Demeuse P, Garcia E, et al. Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem 2005, 93(2): 279-289.
94. Perrière N, Yousif S, Cazaubon S, et al. A functional in vitro model of rat blood-brain barrier for molecular analysis of efflux transporters. Brain Res 2007; 1150: 1-13.
95. Veszelka S, Pásztói M, Farkas AE, et al. Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages. Neurochem Int 2007, 50(1): 219-228.
96. Ge S, Song L, Pachter JS. Where is the blood-brain barrier... really? J Neurosci Res 2005, 79(4): 421-427.
97. van Bree JB, de Boer AG, Danhof M, Ginsel LA, Breimer DD. Characterization of an "in vitro" blood-brain barrier: effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J Pharmacol Exp Ther 1988, 247(3): 1233-1239.
98. van Bree JB, de Boer AG, Verhoef JC, Danhof M, Breimer DD. Transport of vasopressin fragments across the blood-brain barrier: in vitro studies using monolayer cultures of bovine brain endothelial cells. J Pharmacol Exp Ther 1989, 249(3): 901-905.
99. Eddy EP, Maleef BE, Hart TK, Smith PL. In vitro models to predict blood-brain barrier permeability. Adv Drug Deliv Rev 1997, 23(1-3): 185-198.
100. Otis KW, Avery ML, Broward-Partin SM, et al. Evaluation of the BBMEC model for screening the CNS permeability of drugs. J Pharmacol Toxicol Methods 2001, 45(1): 71-77.
101. Hansen DK, Scott DO, Otis KW, Lunte SM. Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling. J Pharm Biomed Anal 2002, 27(6): 945-958.
102. Culot M, Lundquist S, Vanuxeem D, et al. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening. Toxicol in Vitro 2008, 22(3): 799-811.
103. Dehouck M-P, Méresse S, Delorme P, Fruchart JC, Cecchelli R. An easier, reproducible, and mass-production method to study the blood-brain barrier in vitro. J Neurochem 1990, 54(5): 1798-1801.
104. Dehouck M-P, Méresse S, Dehouck B, Fruchart JC, Cecchelli R. In vitro reconstituted blood-brain barrier. J ControlRelease 1992, 21(1-3): 81-92.
105. Cecchelli R, Dehouck B, Descamps L, et al. In vitro model for evaluating drug transport across the blood-brain barrier. Adv Drug Deliv Rev 1999, 36(2-3): 165-178.
106. Jolliet P, Nion S, Allain-Veyrac G, et al. Evidence of lowest brain penetration of an antiemetic drug, metopimazine, compared to domperidone, metoclopramide and chlorpromazine, using an in vitro model of the blood-brain barrier. Pharmacol Res 2007, 56(1): 11-17.
107. Denora N, Laquintana V, Lopedota A, et al. Novel L-Dopa and dopamine prodrugs containing a 2-phenyl-imidazopyridine moiety. Pharm Res 2007, 24(7): 1309-1324.
108. Malakoutikhah M, Prades R, Teixidó M, Giralt E. N-methyl phenylalanine-rich peptides as highly versatile blood-brain barrier shuttles. J Med Chem 2010, 53(6): 2354-2363.
109. Megard I, Garrigues A, Orlowski S, et al. A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation. Brain Res 2002, 927(2): 153-167.
110. Josserand V, Pélerin H, de Bruin B, et al. Evaluation of drug penetration into the brain: a double study by in vivo imaging with positron emission tomography and using an in vitro model of the human blood-brain barrier. J Pharmacol Exp Ther. 2006, 316(1): 79-86.
111. Coisne C, Dehouck L, Faveeuw C, et al. Mouse syngenic in vitro blood-brain barrier model: a new tool to examine inflammatory events in cerebral endothelium. Lab Invest 2005, 85(6): 734-746.
112. Franke H, Galla H-J, Beuckmann CT. An improved low permeability in vitro-model of the blood-brain barrier: transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain Res 1999, 818(1): 65-71.
113. Lohmann C, Hüwel S, Galla HJ. Predicting blood-brain barrier permeability of drugs: evaluation of different in vitro assays. J Drug Target 2002, 10(4): 263-276.
114. Härtter S, Hüwel S, Lohmann T, et al. How does the benzamide antipsychotic amisulpride get into the brain? An in vitro approach comparing amisulpride with clozapine. Neuropsychopharmacology 2003, 28(11): 1916-1922.
115. Zhang Y, Li CSW, Ye Y, et al. Porcine brain microvessel endothelial cells as an in vitro model to predict in vivo bloodbrain barrier permeability. Drug Metab Dispos 2006, 34(11): 1935-1943.
116. Krizanac-Bengez L, Kapural M, Parkinson F, et al. Effects of transient loss of shear stress on blood-brain barrier endothelium: role of nitric oxide and IL-6. Brain Res 2003, 977(2): 239-246.
117. Krizanac-Bengez L, Mayberg MR, Cunningham E, et al. Loss of shear stress induces leukocyte-mediated cytokine release and blood-brain barrier failure in dynamic in vitro blood-brain barrier model. J Cell Physiol 2006, 206(1): 68-77.
118. Bowman PD, Ennis SR, Rarey KE, Betz AL, Goldstein GW. Brain microvessel endothelial cells in tissue culture: a model for study of blood-brain barrier permeability. Ann Neurol 1983, 14(4): 396-402.
119. Kása P, Pákáski M, Joó F, Lajtha A. Endothelial cells from human fetal brain microvessels may be nociceptive, but do not synthesize acetylcholine. J Neurochem 1991, 56(6): 2143-2146.
120. Zenker D, Begley D, Bratzke H, Rübsamen-Waigmann H, von Briesen H. Human blood-derived macrophages enhance barrier function of cultured primary bovine and human brain capillary endothelial cells. J Physiol 2003, 551(Pt3): 1023-1032.
121. Liu NQ, Lossinsky AS, Popik W, et al. Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol 2002, 76(13): 6689-6700.
122. Weidenfeller C, Schrot S, Zozulya A, Galla H-J. Murine brain capillary endothelial cells exhibit improved barrier properties under the influence of hydrocortisone. Brain Res 2005, 1053(1-2): 162-174.
123. Deli MA, Ábrahám CS, Niwa M, Falus A. N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine increases the permeability of primary mouse cerebral endothelial cell monolayers. Inflamm Res 2003; 52(Suppl 1): S39-S40.
124. Hoheisel D, Nitz T, Franke H, et al. Hydroocortisone reinforces the blood-brain barrier properties in a serum free cell culture system. Biochem Biophys Res Commun 1998, 247(2): 312-315.
125. Nitz T, Eisenblätter T, Psathaki K, Galla H-J. Serum-derived factors weaken the barrier properties of cultured porcine brain capillary endothelial cells in vitro. Brain Res 2003, 981(1-2): 30-40.
126. Cohen-Kashi Malina K, Cooper I, Teichberg VI. Closing the gap between the in-vivo and in vitro blood-brain barrier tightness. Brain Res 2009; 1284: 12-21.
127. Smith M, Omidi Y, Gumbleton M. Primary porcine brain microvascular endothelial cells: biochemical and functional characterisation as a model for drug transport and targeting. J Drug Target 2007, 15(4): 253-268.
128. Kis B, Deli MA, Kobayashi H. Adrenomedullin regulates blood-brain barrier functions in vitro. Neuroreport 2001, 12(18): 4139-4142.
129. Sobue K, Yamamoto N, Yoneda K, et al. Induction of blood-brain barrier properties in immortalized bovine brain endothelial cells by astrocytic factors. Neurosci Res 1999; 35(2): 155-164
130. Kusch-Poddar M, Drewe J, Fux I, Gutmann H. Evaluation of the immortalized human brain capillary endothelial cell line BB19 as a human cell culture model for the blood-brain barrier. Brain Res 2005, 1064(1-2): 21-31.
131. Zysk G, Schneider-Wald BK, Hwang JH, et al. Pneumolysin is the main inducer of cytotoxicity to brain microvascular endothelial cells caused by Streptococcus pneumoniae. Infect Immun 2001, 69(2): 845-852.
132. Kannan R, Chakrabarti R, Tang D, Kim KJ, Kaplowitz N. GSH transport in human cerebrovascular endothelial cells and human astrocytes: evidence for luminal localization of Na+-dependent GSH transport in HCEC. Brain Res 2000, 852(2): 374-382.
133. Weksler BB, Subileau EA, Perrière N, et al. Blood-brain barrier-specific properties of a human adult brain endothelial cellline. FASEB J 2005, 19(13): 1872-1874.
134. Poller B, Gutmann H, Krähenbühl S, et al. The human brain endothelial cell line hCMEC/D3 as a human blood-brain barrier model for drug transport studies. J Neurochem 2008, 107(5): 1358-1368.
135. Sharp CD, Hines I, Houghton J, et al. Glutamate causes a loss in human cerebral endothelial barrier integrity through activation of NMDA receptor. Am J Physiol Heart Circ Physiol 2003; 285(6): H2592-H2598.
136. Ketabi-Kiyanvash N, Herold-Mende C, Kashfi F, et al. NKIM-6, a new immortalized human brain capillary endothelial cell line with conserved endothelial characteristics. Cell Tissue Res 2007, 328(1): 19-29.
137. Muruganandam A, Herx LM, Monette R, Durkin JP, Stanimirovic DB. Development of immortalized human cerebromicrovascular endothelial cell line as an in vitro model of the human blood-brain barrier. FASEB J 1997, 11(13): 1187-1197.
138. Muruganandam A, Smith C, Ball R, Herring T, Stanimirovic D. Glutathione homeostasis and leukotriene-induced permeability in human blood-brain barrier endothelial cells subjected to in vitro ischemia. Acta Neurochir Suppl 2000; 76: 29-34.
139. Gu X, Zhang J, Brann DW, Yu FS. Brain and retinal vascular endothelial cells with extended life span established by ectopic expression of telomerase. Invest Ophthalmol Vis Sci 2003, 44(7): 3219-3225.
140. Omidi Y, Campbell L, Barar J, Connell D, Akhtar S, Gumbleton M. Evaluation of the immortalised mouse brain capillary endothelial cell line, bEnd3, as an in vitro blood-brain barrier model for drug uptake and transport studies. Brain Res 2003, 990(1-2): 95-112.
141. Tan KH, Dobbie MS, Felix RA, Barrand MA, Hurst RD. A comparison of the induction of immortalized endothelial cell impermeability by astrocytes. Neuroreport 2001, 12(7): 1329-1334.
142. Förster C, Silwedel C, Golenhofen N, et al. Occludin as direct target for glucocorticoid-induced improvement of bloodbrain barrier properties in a murine in vitro system. J Physiol 2005, 565(Pt 2): 475-486.
143. Hart MN, VanDyk LF, Moore SA, Shasby DM, Cancilla PA. Differential opening of the brain endothelial barrier following neutralization of the endothelial luminal anionic charge in vitro. J Neuropathol Exp Neurol 1987, 46(2): 141-153.
144. Hosoya KI, Takashima T, Tetsuka K, et al. mRNA expression and transport characterization of conditionally immortalized rat brain capillary endothelial cell lines; a new in vitro BBB model for drug targeting. J Drug Target 2000, 8(6): 357-370.
145. Neuhaus W, Lauer R, Oelzant S, Fringeli UP, Ecker GF, Noe CR. A novel flow based hollow-fiber blood-brain barrier in vitro model with immortalised cell line PBMEC/C1-2. J Biotechnol 2006, 125(1): 127-141.
146. Lechardeur D, Schwartz B, Paulin D, Scherman D. Induction of blood-brain barrier differentiation in a rat brain-derived endothelial cell line. Exp Cell Res 1995, 220(1): 161-170.
147. Greenwood J, Pryce G, Devine L, et al. SV40 large T immortalised cell lines of the rat blood-brain and blood-retinal barriers retain their phenotypic and immunological characteristics. J Neuroimmunol 1996, 71(1-2): 51-63.
148. Roux F, Couraud P-O. Rat brain endothelial cell lines for the study of blood-brain barrier permeability and transport functions. Cell Mol Neurobiol 2005, 25(1): 41-58.
149. Régina A, Romero IA, Greenwood J, et al. Dexamethasone regulation of P-glycoprotein activity in an immortalized rat brain endothelial cell line, GPNT. J Neurochem 1999, 73(5): 1954-1963.
150. Blasig IE, Giese H, Schroeter ML, et al. *NO and oxyradical metabolism in new cell lines of rat brain capillary endothelial cells forming the blood-brain barrier. Microvasc Res 2001, 62(2): 114-127.
151. Cerletti A, Drewe J, Fricker G, Eberle AN, Huwyler J. Endocytosis and transcytosis of an immunoliposome-based brain drug delivery system. J Drug Target 2000, 8(6): 435-446.
152. Cestelli A, Catania C, D'Agostino S, et al. Functional feature of a novel model of blood brain barrier: studies on permeation of test compounds. J Control Release 2001, 76(1-2): 139-147.
153. Balbuena P, Li W, Magnin-Bissel G, Meldrum JB, Ehrich M. Comparison of two blood-brain barrier in vitro systems: cytotoxicity and transfer assessments of malathion/oxon and lead acetate. Toxicol Sci 2010, 114(2): 260-271.
154. Faria A, Pestana D, Teixeira D, et al. Flavonoid transport across RBE4 cells: A blood-brain barrier model. Cell Mol Biol Lett 2010, 15(2): 234-241.
155. Kido Y, Tamai I, Okamoto M, Suzuki F, Tsuji A. Functional clarification of MCT1-mediated transport of monocarboxylic acids at the blood-brain barrier using in vitro cultured cells and in vivo BUI studies. Pharm Res 2000, 17(1): 55-62.
156. Terasaki T, Ohtsuki S, Hori S, Takanaga H, Nakashima E, Hosoya K. New approaches to in vitro models of blood-brain barrier drug transport. Drug Discov Today 2003, 8(20): 944-954.
157. Ohtsuki S, Sato S, Yamaguchi H, Kamoi M, Asashima T, Terasaki T. Exogenous expression of claudin-5 induces barrier properties in cultured rat brain capillary endothelial cells. J Cell Physiol 2007, 210(1): 81-86.
158. Teifel M, Friedl P. Establishment of the permanent microvascular endothelial cell line PBMEC/C1-2 from porcine brains. Exp Cell Res 1996, 228(1): 50-57.
159. Kusuhara H, Suzuki H, Naito M, Tsuruo T, Sugiyama Y. Characterization of efflux transport of organic anions in a mouse brain capillary endothelial cell line. J Pharmacol Exp Ther 1998, 285(3): 1260-1265.
160. Tsuji A, Tamai II. Carrier-mediated or specialized transport of drugs across the blood-brain barrier. Adv Drug Deliv Rev 1999, 36(2-3): 277-290.
161. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 1). Drug Discov Today 2001, 6(3): 150-156.
162. Kusuhara H, Sugiyama Y. Efflux transport systems for drugs at the blood-brain barrier and blood-cerebrospinal fluid barrier (Part 2). Drug Discov Today 2001, 6(4): 206-212.
163. Schiera G, Sala S, Gallo A, et al. Permeability properties of a three-cell type in vitro model of blood-brain barrier. J Cell Mol Med 2005, 9(2): 373-379.
164. Ohno K, Pettigrew KD, Rapoport SI. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am J Physiol 1978; 235(3): H299-H307.
165. Oldendorf WH. Measurement of brain uptake of radiolabeled substances using a tritiated water internal standard. Brain Res 1970, 24(2): 372-376.
166. Kusuhara H, Terasaki T, Sugiyama Y. Brain efflux index method. Characterization of efflux transport across the bloodbrain barrier. Methods Mol Med 2003; 89: 219-231.
167. Smith QR. A review of blood-brain barrier transport techniques. In: Nag S, Ed. The Blood-Brain Barrier: Biology and Research Protocols, Vol. 89, Methods Molecular Medicine, Totowa, NJ, Humana Press, 2003; pp. 193-208.
168. Sokoloff L, Reivich M, Kennedy C, et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977, 28(5): 897-916.
169. Tofts PS, Kermode AG. Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med 1991, 17(2): 357-367.
170. Zaharchuk G. Theoretical basis of hemodynamic MR imaging techniques to measure cerebral blood volume, cerebral blood flow, and permeability. Am J Neuroradiol 2007, 28(10): 1850-1858.
171. Hülper P, Dullin C, Kugler W, Lakomek M, Erdlenbruch B. Monitoring proteins using in vivo near-infrared time-domain optical imaging after 2-O-hexyldiglicerol-mediated transfer to the brain. Mol Imaging Biol 2010 in press (doi: 10.1007/s11307-010-0348-3)
172. Lockwood AH. Functional evaluation of the blood-brain barrier using positron emission tomography. Ann Neurol 1984; 15(Suppl): S103-S106.
173. Iannotti F. Functional imaging of blood brain barrier permeability by single photon emission computerised tomography and positron emission tomography. Adv Tech Stand Neurosurg 1992; 19: 103-119.
174. de Lange EC, Danhof M, de Boer AG, Breimer DD. Methodological considerations of intracerebral microdialysis in pharmacokinetic studies on drug transport across the blood-brain barrier. Brain Res Rev 1997, 25(1): 27-49.
175. Collins JM, Dedrick RL. Distributed model for drug delivery to CSF and brain tissue. Am J Physiol 1983; 245(3): R303-R310.